| Original language | English |
|---|---|
| Pages (from-to) | 156-158 |
| Number of pages | 3 |
| Journal | American Journal of Cardiology |
| Volume | 169 |
| DOIs | |
| State | Published - Apr 15 2022 |
Bibliographical note
Funding Information:Dr. Kwak is supported by the National Institute on Aging ( 1R24AG064025 ) and receives personal consultation fees from the Endocrine and Diabetes Plus Clinic of Houston. Dr. Goyal is supported by the American Heart Association grant 20CDA35310455 , National Institute on Aging grant K76AG064428 , and Loan Repayment Program award L30AG060521; receives personal fees for medicolegal consulting related to heart failure; and has received honoraria from Akcea Inc and Bionest Inc. Dr. Kim receives personal fees from Alosa Health and research funding from the National Institute of Health for projects unrelated to the present work. Dr. Holmes received research funding from Healthcare Services Corporation, which is a foundation of Blue Cross Blue Shield, for a study of deprescribing. The funding is unrelated to the manuscript under consideration. Dr. Aparasu receives research funding from Astellas Inc., Incyte Corp., Gilead, and Novartis Inc. for projects unrelated to the current work. The remaining authors have no conflicts of interest to declare.
Funding Information:
This study was supported by National Institute on Aging (Bethesda, Marylnad) grant number 1R24AG064025 (US Deprescribing Research Network Pilot Grant).
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
